Of note, as emphasized in the adult ELN 2017 risk classification (see Table 3), FLT3-ITD mutations should not be used as adverse prognostic markers if they occur within favorable cytogenetic risk groups such as CBF leukemia. The gene discussed is FLT3; the disease is leukemia.